Induction and inhibition of innate inflammatory responses by adenovirus early region proteins

Viral Immunology

Volumn 18, Issue 1, 2005, Pages 79-88

  Schaack, Jerome ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; E1B PROTEIN; GENE PRODUCT; PROTEIN E3; UNCLASSIFIED DRUG; VIRUS PROTEIN;

GENE CONSTRUCT; GENE DELETION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC CODE; GENETIC TRANSDUCTION; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INHIBITION KINETICS; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION INITIATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; VIRUS GENE; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ADENOVIRUS EARLY PROTEINS; ANIMALS; APOPTOSIS; DNA, VIRAL; GENE DELETION; GENETIC VECTORS; HUMANS; INFLAMMATION;

ADENOVIRIDAE; MIRIDAE;

EID: 17844402009     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.79     Document Type: Review

References (82)

1. Adam, S.A., and G. Dreyfuss (1987). Adenovirus proteins associated with mRNA and hnRNA in infected HeLa cells. J. Virol. 61: 3276-3283.
2. Amalfitano, A., M.A. Hauser, H. Hu, et al. (1998). Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. 72:926-933.
3. Anderson, K.P., and E.H. Fennie. (1987). Adenovirus early region 1A modulation of interferon antiviral activity. J. Virol. 61:787-795.
4. Armentano, D., J. Zabner, C. Sacks, et al. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71:2408-2416.
5. Boyer, J., K. Rohleder, and G. Ketner. (1999). Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307-312.
6. Chen, M.J., B. Holskin, J. Strickler, et al. (1987). Induction by E1A oncogene expression of cellular susceptibility to lysis by TNF. Nature 330:581-583.
7. Christ, M., B. Louis, F. Stoeckel, et al. (2000). Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum. Gene Ther. 11:415-427.
8. Cleghon, V.G., and D.F. Klessig. (1986). Association of the adenovirus DNA-binding protein with RNA both in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 83:8947-8951.
9. Cuconati, A., and E. White. (2002). Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev. 16:2465-2478.
10. de Jong, R.N., P.C. van der Vliet, and A.B. Brenkman. (2003). Adenovirus DNA replication: protein priming, jumping back and the role of the DNA binding protein DBP. Curr. Top. Microbiol. Immunol. 272:187-211.
11. Dedieu, J.F., E. Vigne, C. Torrent, et al. (1997). Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J. Virol. 71:4626-4637.
12. Deryckere, F., and H.G. Burgert. (1996). Tumor necrosis factor-alpha induces the adenovirus early 3 promoter by activation of NF-kappaB. J. Biol. Chem. 271:30249-30255.
13. Dobner, T., N. Horikoshi, S. Rubenwolf, et al. (1996). Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 272:1470-1473.
14. Doerfler, W., and P.E. Böhm, eds. (2003). Curr. Top. Microbiol. Immunol. 272.
15. Doerfler, W., and P.E. Böhm, eds. (2004). Curr. Top. Microbiol. Immunol. 273.
16. Duncan, S.J., F.C. Gordon, D.W. Gregory, et al. (1978). Infection of mouse liver by human adenovirus type 5. J. Gen. Virol. 40:45-61.
17. Estmer Nilsson, C., S. Petersen-Mahrt, C. Durot, et al. (2001). The adenovirus E4-ORF4 splicing enhancer protein interacts with a subset of phosphorylated SR proteins. EMBO J. 20:864-871.
18. Everett, R.S., B.L. Hodges, E.Y. Ding, et al. (2003). Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. Hum. Gene Ther. 14:1715-1726.
19. Fessier, S.P., F. Delgado-Lopez, and M.S. Horwitz. (2004). Mechanisms of E3 modulation of immune and inflammatory responses. Curr. Top. Microbiol. Immunol. 273:113-135.
20. Fisher, K.J., H. Choi, J. Burda, et al. (1996). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217:11-22.
21. Flint, J., and T. Shenk. (1989). Adenovirus E1A protein paradigm viral transactivator. Annu. Rev. Genet. 23: 141-161.
22. Flint, S.J., and R.A. Gonzalez. (2003). Regulation of mRNA production by the adenoviral E1B 55-kDa and E4 Orf6 proteins. Curr. Top. Microbiol. Immunol. 272: 287-330.
23. Frisch, S.M., and J.S. Mymryk. (2002). Adenovirus-5 E1A: paradox and paradigm. Nat. Rev. Mol. Cell Biol. 3: 441-452.
24. Gallimore, P.H., and A.S. Turnell. (2001). Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 20:7824-7835.
25. Gantzer, M., E. Spitz, N. Accard, et al. (2002). Constitutive expression of the adenovirus E3-14.7K protein does not prolong adenovirus vector DNA persistence but protects mice against lipopolysaccharide-induced acute hepatitis. Hum. Gene Ther. 13:921-933.
26. Glenn, G.M., and R.P. Ricciardi. (1988). Detailed kinetics of adenovirus type-5 steady-state transcripts during early infection. Virus Res. 9:73-91.
27. Gooding, L.R., L.W. Elmore, A.E. Tollefson, et al. (1988). 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell 53:341-346.
28. Gorziglia, M.I., M.J. Kadan, S. Yei, et al. (1996). Elimination of both E1 and E2a from adenovirus vectors further improves prospects for in vivo human gene therapy. J. Virol. 70:4173-4178.
29. Hardy, S., D.A. Engel, and T. Shenk. (1989). An adenovirus early region 4 gene product is required for induction of the infection-specific form of cellular E2F activity. Genes Dev. 3:1062-1074.
30. Harrod, K.S., T.W. Hermiston, B.C. Trapnell, et al. (1998). Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression. Hum. Gene Ther. 9:1885-1898.
31. Hasson, T.B., P.D. Soloway, D.A. Ornelles, et al. (1989). Adenovirus L1 52- and 55-kilodalton proteins are required for assembly of virions. J. Virol. 63:3612-3621.
32. Herz, J., and R.D. Gerard. (1993). Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc. Natl. Acad. Sci. USA 90:2812-2816.
33. Ilan, Y., G. Droguett, N.R. Chowdhury, et al. (1997). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 94:2587-2592.
34. Janaswami, P.M., D.V. Kalvakolanu, Y. Zhang, et al. (1992). Transcriptional repression of interleukin-6 gene by adenoviral E1A proteins. J. Biol. Chem. 267: 24886-24891.
35. Kitajewski, J., R.J. Schneider, B. Safer, et al. (1986). Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2 alpha kinase. Cell 45:195-200.
36. Labow, D., S. Lee, R.J. Ginsberg, et al. (2000). Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum. Gene Ther. 11:759-769.
37. Lanuti, M., G.P. Gao, S.D. Force, et al. (1999). Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum. Gene Ther. 10:463-475.
38. Leonard, G.T., and G.C. Sen. (1996). Effects of adenovirus E1A protein on interferon-signaling. Virology 224:25-33.
39. Lichtenstein, D.L., K. Toth, K. Doronin, et al. (2004). Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23:75-111.
40. Lichtenstein, D.L., and W.S. Wold. (2004). Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 10:1-11.
41. Liu, H., J.H. Naismith, and R.T. Hay. (2003). Adenovirus DNA replication. Curr. Top. Microbiol. Immunol. 272: 131-164.
42. Liu, Q., and D.A. Muruve. (2003). Molecular basis of the inflammatory response to adenovirus vectors. Gene Ther. 10:935-940.
43. Liu, Q., A.K. Zaiss, P. Colarusso, et al. (2003). The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum. Gene Ther. 14:627-643.
44. Lusky, M., M. Christ, K. Rittner, et al. (1998). In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J. Virol. 72:2022-2032.
45. Marcellus, R.C., H. Chan, D. Paquette, et al. (2000). Induction of p53-independent apoptosis by the adenovirus E4orf4 protein requires binding to the B alpha subunit of protein phosphatase 2A. J. Virol 74:7869-7877.
46. Mellits, K.H., M. Kostura, and M.B. Mathews. (1990). Interaction of adenovirus VA RNA1 with the protein kinase DAI: nonequivalence of binding and function. Cell 61:843-852.
47. Mittereder, N., S. Yei, C. Bachurski, et al. (1994). Evaluation of the efficacy and safety of in vitro, adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA. Hum. Gene Ther. 5:717-729.
48. Montell, C., E.F. Fisher, M.H. Caruthers, et al. (1984). Control of adenovirus E1B mRNA synthesis by a shift in the activities of RNA splice sites. Mol. Cell. Biol. 4:966-972.
49. Moorhead, J.W., G.H. Clayton, R.L. Smith, et al. (1999). An adenovirus vector deleted for the preterminal protein gene elicits reduced inflammation in mouse ears. J. Virol. 73:1046-1053.
50. Moran, E. (1993). Interaction of adenoviral proteins with pRB and p53. FASEB J. 7:880-885.
51. Mori, K., R. Juttermann, U. Wienhues, et al. (1996). Anti-interferon activity of adenovirus-2-encoded VAI and VAII RNAs in translation in cultured human cells. Virus Res. 42:53-63.
52. Morsy, M.A., M. Gu, S. Motzel, et al. (1998). An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc. Natl. Acad. Sci. U.S.A. 95:7866-7871.
53. Muruve, D.A., M.J. Barnes, I.E. Stillman, et al. (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10:965-976.
54. Muruve, D.A., M.J. Cotter, A.K. Zaiss, et al. (2004). Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 78:5966-5972.
55. Nelson, J.E., and M.A. Kay. (1997). Persistence of recombinant adenovirus in vivo is not dependent on vector DNA replication. J. Virol. 71:8902-8907.
56. Parks, R.J., L. Chen, M. Anton, et al. (1996). A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc. Natl. Acad. Sci. USA 93:13565-13570.
57. Parks, R.J., and F.L. Graham. (1997). A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. Virology 71:3293-3298.
58. Qian, H.S., K. Channon, V. Neplioueva, et al. (2001). Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ. Res. 88:911-917.
59. Reich, N., R. Pine, D. Levy, et al. (1988). Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. J. Virol. 62:114-119.
60. Rice, S.A., and D.F. Klessig. (1985). Isolation and analysis of adenovirus type 5 mutants containing deletions in the gene encoding the DNA-binding protein. J. Virol. 56:767-778.
61. Schaack, J., M.L. Bennett, J. Colbert, et al. (2004). E1A and E1B proteins inhibit inflammation induced by adenovirus. Proc. Natl. Acad. Sci. USA 101:3124-3129.
62. Schaack, J., X. Guo, and S. Langer. (1996). Characterization of a replication-incompetent adenovirus type 5 mutant deleted for the preterminal protein gene. Proc. Natl. Acad. Sci. USA 93:14686-14691.
63. Schowalter, D.B., J.C. Tubb, M. Liu, et al. (1997). Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo. Gene Ther. 4:351-360.
64. Shenk, T., and J. Flint (1991). Transcriptional and transforming activities of the adenovirus E1A proteins. Adv. Cancer Res. 57:47-85.
65. Shenk, T., N. Jones, W. Colby, et al. (1979). Functional analysis of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp. Quant. Biol. 44:367-375.
66. Smith, T.A., M.G. Mehaffey, D.B. Kayda, et al. (1993). Adenovirus-mediated expression of therapeutic plasma levels of human factor K in mice. Nat. Genet. 5:397-402.
67. Stein, C.S., J.L. Pemberton, N. van Rooijen, et al. (1998). Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther. 5:431-439.
68. Straus, S.E. (1984). Adenovirus infections in humans, pp. 451-496. In: H.S. Ginsberg (ed.), The Adenoviruses. Plenum, New York.
69. Takeda, T., K. Nakajima, H. Kojima, et al. (1994). E1A repression of IL-6-induced gene activation by blocking the assembly of IL-6 response element binding complexes. J. Immunol. 153:4573-4582.
70. Thomas, G.P., and M.B. Mathews. (1980). DNA replication and the early to late transition in adenovirus infection. Cell 22:523-533.
71. Weinberg, D.H., and G. Ketner. (1986). Adenoviral early region 4 is required for efficient viral DNA replication and for late gene expression. J Virol. 57:833-838.
72. Wen, S., M. Driscoll, R.D.B. Schneider, et al. (2001). Inclusion of the E3 region in an adenoviral vector decreases inflammation and neointima formation after arterial gene transfer. Arterioscler. Thromb. Vasc. Biol. 21:1777-1782.
73. Wilson, C.B., L.J. Embree, D. Schowalter, et al. (1998). Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J. Virol. 72:7542-7550.
74. Windheim, M., A. Hilgendorf, and H.G. Burgert. (2004). Immune evasion by adenovirus E3 proteins: exploitation of intracellular trafficking pathways. Curr. Top. Microbiol. Immunol. 273:29-85.
75. Yang, Y., S.E. Haecker, Q. Su, et al. (1996). Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum. Mol. Genet. 5:1703-1712.
76. Yang, Y., K.U. Jooss, Q. Su, et al. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:137-144.
77. Yang, Y., Q. Li, and J.M. Wilson. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69:2004-2015.
78. Yang, Y., P.A. Nunes, K. Berencsi, et al. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91:4407-4411.
79. Yeh, P., J.F. Dedieu, C. Orsini, et al. (1996). Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J. Virol. 70:559-565.
80. Zaiss, A.K., Q. Liu, G.P. Bowen, et al. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76:4580-4590.
81. Zhang, Y., N. Chirmule, G.P. Gao, et al. (2001). Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3:697-707.
82. Zsengeller, Z.K., G.P. Boivin, S.S. Sawchuk, et al. (1997). Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer. Hum. Gene Ther. 8:935-941.